Innolife Pharma

Innolife is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in regenerative medicine for ischemic organ failure. Founded in 2014 by Dr. Y. James Kang, the company develops therapies based on the "tissue injury signaling system" theory, which focuses on mobilizing the body's inherent self-repair capabilities through the regulation of trace elements. Its lead candidate, INL1 (trientine hydrochloride), is a small molecule copper redistribution shuttle currently in Phase 2 clinical trials in the United States for the treatment of heart failure with reduced ejection fraction (HFrEF). INL1 was notably recognized by the European Society of Cardiology as one of the "Top 10 Breakthrough Studies of 2023." The company's broader pipeline includes programs targeting cerebral infarction, hypertension, atherosclerosis, and liver fibrosis.